



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

产品名称: **BENZIMIDAVIR 苯并咪唑核苷**  
产品别名: **Maribavir ; 马立巴韦; 1263W94; BW1263W94; GW257406X**

生物活性:				
Description	Maribavir is a potent inhibitor of histone phosphorylation catalyzed by wild-type pUL97 in vitro, with an IC <sub>50</sub> of 3 nM. Maribavir has potent antiviral activity against HCMV and Epstein-Barr virus (EBV).			
IC <sub>50</sub> & Target	HCMV <sup>[1]</sup>			
In Vitro	Maribavir is a potent inhibitor of the autophosphorylation of the wild type and all the major Ganciclovir (GCV) resistant UL97 mutants analysed with a mean IC <sub>50</sub> of 35 nM. The M460I mutation results in hypersensitivity to Maribavir with an IC <sub>50</sub> of 4.8 nM. A Maribavir resistant mutant of UL97 (L397R) is functionally compromised as both a Ganciclovir kinase and a protein kinase (~ 10% of wild type levels). Enzyme kinetic experiments demonstrate that Maribavir is a competitive inhibitor of ATP with a K <sub>i</sub> of 10 nM <sup>[1]</sup> . Maribavir (1263W94) inhibits viral replication in a dose-dependent manner, with IC <sub>50</sub> of 0.12±0.01 µM as measured by a multicycle DNA hybridization assay. The pUL97 protein kinase is strongly inhibited by Maribavir, with 50% inhibition occurring at 3 nM <sup>[2]</sup> .			
Solvent&Solubility	<b>In Vitro:</b> <b>DMSO : ≥ 51 mg/mL (135.55 mM)</b>  * "≥" means soluble, but saturation unknown.			
	Preparing Stock Solutions	Solvent Concentration	Mass	
			1 mg	
			5 mg	
			10 mg	
		1 mM	2.6579 mL	13.2894 mL
		5 mM	0.5316 mL	2.6579 mL
		10 mM	0.2658 mL	1.3289 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。  储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。  <b>In Vivo:</b>  请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂:  ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶  1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline  Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution  此方案可获得 ≥ 2.5 mg/mL (6.64 mM, 饱和度未知) 的澄清溶液。  以 1 mL 工作液为例, 取 100 µL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 µL PEG300 中, 混合均匀向上述体系中加入 50 µL Tween-80, 混合均匀; 然后继续加入 450 µL 生理盐水定容至 1 mL。  2.请依序添加每种溶剂: 10% DMSO→ 90% (20% SBE-β-CD in saline)  Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution			



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

	<p>此方案可获得 <math>\geq 2.5</math> mg/mL (6.64 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例, 取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 20% 的 SBE-<math>\beta</math>-CD 生理盐水溶液中, 混合均匀。</p> <p>3.请依序添加每种溶剂: 10% DMSO <math>\rightarrow</math> 90% corn oil</p> <p>Solubility: <math>\geq 2.5</math> mg/mL (6.64 mM); Clear solution</p> <p>此方案可获得 <math>\geq 2.5</math> mg/mL (6.64 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 玉米油中, 混合均匀。</p>
References	<p>[1]. Shannon-Lowe CD, et al. The effects of Maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein. Herpesviridae. 2010 Dec 7;1(1):4.</p> <p>[2]. Biron KK, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002 Aug;46(8):2365-72.</p>
实验参考:	
Cell Assay	<p>For these studies MRC-5 cells are seeded in 24-well plates at <math>\sim 5 \times 10^4</math> cells/well and grown for 3 days in MEM 8-1-1 to confluence (<math>\sim 1.1 \times 10^5</math> cells/well). The cells are infected with AD169 in MEM 2-1-1 at an MOI ranging from 1 to 3 and incubated at 37°C for 90 min to allow viral adsorption. The unadsorbed virus is removed and replaced with 1 mL of MEM 2-1-1. To test the effect of compounds on viral DNA synthesis or maturation, Maribavir, BDCRB, or GCV is added to the medium at the concentrations indicated for each experiment<sup>[2]</sup>.</p>
Kinase Assay	<p>Enzyme kinetic analysis is performed on the purified wild type and mutant UL97 protein species using increasing concentrations of ATP (2 <math>\mu</math>M to 20 <math>\mu</math>M). The amount of incorporated radiolabelled phosphate is plotted against the concentration of ATP in a Lineweaver Burke plot to determine the <math>K_m</math> for ATP for each UL97 species. The effect of Maribavir upon the rate of radiolabelled phosphate incorporation by wild type or mutant UL97 is determined by protein kinase assays at a fixed concentration of Maribavir (0.5 <math>\mu</math>M) as above, or with increasing concentrations of Maribavir (0.01 <math>\mu</math>M to 5.0 <math>\mu</math>M) to determine the <math>IC_{50}</math> of Maribavir for each UL97 species. In order to determine the nature of the inhibition mediated by Maribavir, plots of <math>1/v</math> vs <math>1/ATP</math> with increasing concentrations of Maribavir are constructed. Competitive inhibition is evident if the family of lines converged on the y-axis at <math>1/V_{max}</math>. The change in slope caused by the addition of Maribavir is used to calculate the <math>K_i</math><sup>[1]</sup>.</p>
References	<p>[1]. Shannon-Lowe CD, et al. The effects of Maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein. Herpesviridae. 2010 Dec 7;1(1):4.</p> <p>[2]. Biron KK, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002 Aug;46(8):2365-72.</p>